Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.
Company profile
Ticker
PRVB
Exchange
Website
CEO
Ashleigh Palmer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Provention Inc.
SEC CIK
PRVB stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
8 May 23
EFFECT
Notice of effectiveness
1 May 23
EFFECT
Notice of effectiveness
1 May 23
EFFECT
Notice of effectiveness
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Apr 23
Transcripts
PRVB
Earnings call transcript
2022 Q3
3 Nov 22
PRVB
Earnings call transcript
2022 Q2
6 Aug 22
PRVB
Earnings call transcript
2022 Q1
5 May 22
PRVB
Earnings call transcript
2021 Q4
24 Feb 22
PRVB
Earnings call transcript
2021 Q3
4 Nov 21
PRVB
Earnings call transcript
2021 Q2
7 Aug 21
PRVB
Earnings call transcript
2021 Q1
8 May 21
PRVB
Earnings call transcript
2020 Q4
25 Feb 21
PRVB
Earnings call transcript
2020 Q3
7 Nov 20
PRVB
Earnings call transcript
2020 Q2
9 Aug 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.04 mm | 44.04 mm | 44.04 mm | 44.04 mm | 44.04 mm | 44.04 mm |
Cash burn (monthly) | 19.45 mm | 2.85 mm | 13.39 mm | 10.68 mm | 2.66 mm | 6.28 mm |
Cash used (since last report) | 304.54 mm | 44.57 mm | 209.68 mm | 167.24 mm | 41.63 mm | 98.40 mm |
Cash remaining | -260.50 mm | -526.67 k | -165.64 mm | -123.21 mm | 2.41 mm | -54.37 mm |
Runway (months of cash) | -13.4 | -0.2 | -12.4 | -11.5 | 0.9 | -8.7 |
Institutional ownership, Q1 2023
85.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 184 |
Opened positions | 75 |
Closed positions | 29 |
Increased positions | 51 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 1.41 tn |
Total shares | 80.56 mm |
Total puts | 822.00 k |
Total calls | 635.95 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Sessa Capital | 17.76 mm | $427.97 mm |
Sessa Capital IM | 8.88 mm | $213.98 bn |
BLK Blackrock | 5.67 mm | $136.56 bn |
Vanguard | 4.18 mm | $100.70 bn |
Adage Capital Partners GP, L.L.C. | 3.64 mm | $87.75 bn |
Pentwater Capital Management | 3.14 mm | $75.55 bn |
Ubs Oconnor | 2.93 mm | $70.49 bn |
AMGN AMGEN | 2.50 mm | $42.35 mm |
STT State Street | 1.73 mm | $41.75 bn |
Magnetar Financial | 1.48 mm | $35.78 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Apr 23 | Heidy King-Jones | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 8.93 | 200,000 | 1.79 mm | 0 |
27 Apr 23 | Heidy King-Jones | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 4.39 | 145,000 | 636.55 k | 0 |
27 Apr 23 | Heidy King-Jones | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 6.8 | 139,500 | 948.60 k | 0 |
27 Apr 23 | Heidy King-Jones | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 11.23 | 300,000 | 3.37 mm | 0 |
27 Apr 23 | Thierry Chauche | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 8.93 | 200,000 | 1.79 mm | 0 |
27 Apr 23 | Thierry Chauche | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 4.39 | 50,000 | 219.50 k | 0 |
27 Apr 23 | Thierry Chauche | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 6.95 | 375,000 | 2.61 mm | 0 |
27 Apr 23 | Ramos Eleanor | Common Stock | Dispose U | No | No | 0 | 70,000 | 0.00 | 0 | |
27 Apr 23 | Ramos Eleanor | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 8.93 | 210,000 | 1.88 mm | 0 |
27 Apr 23 | Ramos Eleanor | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 4.39 | 145,000 | 636.55 k | 0 |